Puromycin-sensitive aminopeptidase: an antiviral prodrug activating enzyme.

Puromycin-sensitive aminopeptidase: an antiviral prodrug activating enzyme.
复制标题

DOI:
10.1016/j.antiviral.2009.12.003
复制
发表时间:
2010-03
期刊:
影响因子:
7.6
通讯作者:
Amidona, Gordon L.
Amidona, Gordon L.
中科院分区:
医学2区
文献类型:
--
作者:
Tehler, Ulrika;Nelson, Cara H.;Peterson, Larryn W.;Provoda, Chester J.;Hilfinger, John M.;Lee, Kyung-Dall;McKenna, Charles E.;Amidona, Gordon L.

文献摘要

参考文献

被引文献

相似文献

Cidofovir (HPMPC) is a broad-spectrum antiviral agent, currently used to treat AIDS-related human cytomegalovirus retinitis. Cidofovir has recognized therapeutic potential for orthopox virus infections, although its use is hampered by its inherent low oral bioavailability. Val-Ser-cyclic HPMPC (Val-Ser-cHPMPC) is a promising peptide prodrug which has previously been shown by us to improve the permeability and bioavailability of the parent compound in rodent models ( vol 5 598-609). Puromycin-sensitive aminopeptidase was partially purified from Caco-2 cell homogenates and identified as a prodrug activating enzyme for Val-Ser-cHPMPC. The prodrug activation process initially involves an enzymatic step where the l-Valine residue is removed by puromycin-sensitive aminopeptidase, a step that is bestatin-sensitive. Subsequent chemical hydrolysis results in the generation of cHPMPC. A recombinant puromycin-sensitive aminopeptidase was generated and its substrate specificity investigated. The kcat for Val-pNA was significantly lower than that for Ala-pNA, suggesting that some amino acids are preferred over others. Furthermore, the three-fold higher kcat for Val-Ser-cHPMPC as compared to Val-pNA suggests that the leaving group may play an important role in determining hydrolytic activity. In addition to its ability to hydrolyze a variety of substrates, these observations strongly suggest that puromycin-sensitive aminopeptidase is an important enzyme for activating Val-Ser-cHPMPC in vivo. Taken together, our data suggest that puromycin-sensitive aminopeptidase makes an attractive target for future prodrug design.
DOI: 10.1021/mp8000099
发表时间: 2008-07-01
影响因子: 4.9
作者:
Eriksson, Ulrika;Peterson, Larryn W.;McKenna, Charles E.
通讯作者: McKenna, Charles E.
DOI: 10.1039/p29800000373
发表时间: 1980-01-01
期刊: JOURNAL OF THE CHEMICAL SOCIETY-PERKIN TRANSACTIONS 2
影响因子: --
作者:
LAZARUS, RA;BENKOVIC, PA;BENKOVIC, SJ
通讯作者: BENKOVIC, SJ
DOI: 10.1016/j.jorganchem.2005.03.004
发表时间: 2005-05-16
影响因子: 2.3
作者:
McKenna, CE;Kashemirov, BA;Hilfinger, JM
通讯作者: Hilfinger, JM
DOI: 10.1016/0003-9861(90)90724-d
发表时间: 1990-02-01
影响因子: 3.9
作者:
JOHNSON, GD;HERSH, LB
通讯作者: HERSH, LB
DOI: 10.1021/ja00509a043
发表时间: 1979-01-01
影响因子: 15
作者:
LAZARUS, RA;BENKOVIC, SJ
通讯作者: BENKOVIC, SJ